Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. US Oncology Research Inc, The Woodlands, TX, United States



Survival: 27.7 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: The Woodlands, TX
   
Hospital: US Oncology Research Inc
   
Journal: Link
   
Date: 1/2010

Description:
Patients:
This phase 2 study involved 60 relapsed or refractory indolent lymphoma patients who were previously treated with rituximab. The median patient age was 70 years and 47% were male.

Treatment:
Patients were treated with the biologic therapy agent called bortezomib, which is classified as a proteasome inhibitor and interferes with cancer cell growth.

Toxicities:
The most severe toxicities were of grade 4 and included thrombocytopenia and dehydration. Grade 3 neutropenia, fatigue, and diarrhea were also reported.

Results:
The median overall survival was 27.7 months.

Support:
This work was partially supported by Millennium Pharmaceuticals Inc.

Correspondence: Dr. Nicholas Di Bella; email: nick.dibella@usoncology.com

E-mail to a Friend Email Physician More Information